SGMO Insider Trading Activity and SEC Form 4 Filings
SGMO insider trading summary
Over the past 12 months, insiders at Sangamo Therapeutics, Inc (SGMO) reported 2 sales worth $107K by 2 insiders and no open-market purchases on SEC Form 4. Net insider selling was $107K.
Latest SGMO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 22, 2026 | Gregory D Davis | Head of Research & Technology | Sell | $18K (69,827 @ $0.25) |
| Apr 21, 2026 | Nathalie Dubois-Stringfellow | Svp-Chief Development Officer | Sell | $89K (345,942 @ $0.26) |
| Sep 26, 2023 | Biogen Inc. | 10% Owner | Sell | $3.0M (6,000,000 @ $0.50) |
| Sep 26, 2023 | Biogen MA Inc. | 10% Owner | Sell | $3.0M (6,000,000 @ $0.50) |
| Aug 30, 2022 | Biogen MA Inc. | 10% Owner | Sell | $527K (100,000 @ $5.27) |
| Aug 30, 2022 | Biogen Inc. | 10% Owner | Sell | $527K (100,000 @ $5.27) |
| Aug 29, 2022 | Biogen Inc. | 10% Owner | Sell | $2.1M (400,000 @ $5.33) |
| Aug 29, 2022 | Biogen MA Inc. | 10% Owner | Sell | $2.1M (400,000 @ $5.33) |
| Jun 3, 2022 | John Markels | Director | Buy | $25K (6,784 @ $3.69) |
| Jun 1, 2022 | H Stewart Parker | Director | Buy | $18K (5,000 @ $3.60) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.